trop2-car-nk
Cell therapyexperimental
Clinical trial activity
4 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Oct 11, 2023 (NCT05922930)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Tumor-associated calcium signal transducer 2Immunity, passive
TACSTD2 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06358430 | Phase 1 | Oct 31, 2024 | University of Texas at Houston |
| NCT06454890 | Phase 1/Phase 2 (Phase 2) | Aug 1, 2024 | Henan Medical University |
| NCT06066424 | Phase 1 | Oct 24, 2023 | Bellicum Pharmaceuticals, University of Texas at Houston |
| NCT05922930 | Phase 1/Phase 2 (Phase 2) | Oct 11, 2023 | University of Texas at Houston |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| University of Texas at Houston | Academic/Hospital | 3 | 3 | 2 | 2023 |
| Bellicum Pharmaceuticals | For profit | 1 | 0 | 1 | 2023 |
| Henan Medical University | Academic/Hospital | 1 | 1 | 1 | 2024 |
3 organizations
Page 1 / 1